Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Xcelodose boosts Juniper Pharma's CDMO offerings
January 2016
EDIT CONNECT

SHARING OPTIONS:

NOTTINGHAM, U.K.—Juniper Pharma Services, a subsidiary of Juniper Pharmaceuticals Inc., recently announced the expansion of its Xcelodose powder micro-dosing system as part of its suite of GMP capabilities. Xcelodose allows Juniper to accurately fill API directly into capsules to primarily support first-in-human studies, reduce formulation requirements and minimize drug substance wastage. It also enables the automated processing of API directly into capsules at very low doses, offering an ideal approach for highly soluble products and potent molecules.
 
Claire Madden-Smith, senior vice president at Juniper Pharma Services, said: “The increased usage of Xcelodose is a natural expansion of our manufacturing services. Encouragingly, the service is already helping satisfy the growing needs of our clients to get to clinical trials as quickly as possible without compromising on quality. The technique simply allows us to make and supply batches of the drug in capsules for clinic in a much more precise and economical manner.”
 
Code:

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.